Variations in tissue selectivity amongst insulin secretagogues: a systematic review (Q37933466)

25 August 2017

1 reference

title

Variations in tissue selectivity amongst insulin secretagogues: a systematic review (English)

1 reference

25 August 2017

1 reference

1 reference

A S Abdelmoneim

1

1 reference

25 August 2017

S E Hasenbank

2

1 reference

25 August 2017

J M Seubert

3

1 reference

25 August 2017

D R Brocks

4

1 reference

25 August 2017

P E Light

5

1 reference

25 August 2017

S H Simpson

6

1 reference

25 August 2017

3 November 2011

1 reference

Diabetes, Obesity and Metabolism

25 August 2017

1 reference

25 August 2017

14

1 reference

25 August 2017

2

1 reference

25 August 2017

130-138

1 reference

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Electrophysiology of the pancreatic beta-cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Sulphonylurea action revisited: the post-cloning era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Preconditioning: a paradigm shift in the biology of myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Determinants of Hospital Admission and Case Fatality in Diabetic Patients With Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Sulfonylurea stimulation of insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Pharmacokinetics of tolbutamide in ethnic Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Clinical pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Glimepiride pharmacokinetics in obese versus non-obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Reconstituted human cardiac KATP channels: functional identity with the native channels from the sarcolemma of human ventricular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Inhibition of recombinant K(ATP) channels by the antidiabetic agents midaglizole, LY397364 and LY389382.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Enantioselective pharmacokinetics of etodolac in the rat: tissue distribution, tissue binding, and in vitro metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Kinetic Analysis of the Inhibitory Effect of Glibenclamide on K ATP Channels of Mammalian Skeletal Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01496.X

10.1111/J.1463-1326.2011.01496.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference